Factors associated with 6-min walk distance in severe asthma: A cross-sectional study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 829 KB, PDF-dokument
Background and objective: Exercise capacity is associated with health-related quality of life and symptom control in severe asthma. Thus, interventions targeting exercise capacity are likely to be beneficial. However, clinical and biological factors impacting exercise capacity in severe asthma are sparsely investigated. We aimed to describe the association of selected clinical and biological factors with 6-min walk distance (6MWD) in adults with severe asthma and investigate the impact of sex on these outcomes. Methods: A cross-sectional study in adults with severe asthma was conducted. Exercise capacity was measured by 6-min walk test, and association between 6MWD and predictors were evaluated using multiple linear regression. Results: A total of 137 patients (females, 85; median age, 59 years) were recruited. Overall, asthma control (−15.2 m, 95% CI −22.6 to −7.7; p = 0.0001) and BMI (−3.2 m, 95% CI −5.1 to −1.3; p = 0.001) were significantly associated with exercise capacity (adjusted variance, adj. R2 = 0.425). In females, 5-item Asthma Control Questionnaire (ACQ-5; p = 0.005) and BMI (p < 0.001) were significantly associated with 6MWD (adj. R2 = 0.423). In males, a 0.5-point increase in ACQ-5 was associated with a decrease in 6MWD by 10.2 m (95% CI −22.8 to 2.4; p = 0.11), but no clinical nor biological factors reached statistical significance (adj. R2 = 0.393). Conclusion: Asthma symptoms and BMI were associated with exercise capacity in the overall population. Optimizing these factors may enhance the ability of patients to improve their exercise capacity and gain the associated positive health outcomes, but further studies are warranted.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Respirology |
| Vol/bind | 27 |
| Udgave nummer | 12 |
| Sider (fra-til) | 1025-1033 |
| Antal sider | 9 |
| ISSN | 1323-7799 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
Vanessa M. McDonald was supported by an NHMRC TRIP fellowship; has participated in educational symposia funded by GlaxoSmithKline, AstraZeneca, Menarini and Novartis; and has participated in advisory boards for GlaxoSmithKline, AstraZeneca and Menarini. Peter G. Gibson holds an NHMRC Practitioner Fellowship; has participated in educational symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; and has participated in studies funded by GlaxoSmithKline and AstraZeneca. Vibeke Backer reports grants and/or consulting and/or lecture fees from UNION therapeutics, Chiesi, Novartis, SanofiGenzyme, Pharmaxis, GlaxoSmithKline, Boehringer‐Ingelheim and TEVA; had travel expenses to congress meeting covered by SanofiGenzyme; is advisory board member at TEVA, Chiesi, AstraZeneca, SanofiGenzyme, Novartis and ALK‐Abello; and has received study medication from Novartis. Vanessa L. Clark receives a fellowship from the National Health and Medical Research Council Centre of Research Excellence in Severe Asthma. Anders Pitzner‐Fabricius has no conflicts of interest.
Funding Information:
The authors would like to acknowledge the participants enrolled in the study. We also acknowledge the clinical research team involved in the outcome assessment, including Kelly Steel (John Hunter Hospital, Newcastle, Australia), Amber Smith, Penny Baines and Michelle Rostas (University of Newcastle, Newcastle, Australia), and the laboratory processing team at the Priority Research Centre for Healthy Lungs. Open access publishing facilitated by The University of Newcastle, as part of the Wiley - The University of Newcastle agreement via the Council of Australian University Librarians.
Publisher Copyright:
© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
ID: 329278719